This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Epizyme Crescita futura
Future criteri di controllo 2/6
Informazioni chiave
15.8%
Tasso di crescita degli utili
16.6%
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 35.6% |
Tasso di crescita dei ricavi | 37.6% |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | Low |
Ultimo aggiornamento | n/a |
Aggiornamenti recenti sulla crescita futura
Recent updates
Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2024 | 136 | -173 | N/A | N/A | 3 |
12/31/2023 | 80 | -196 | N/A | N/A | 4 |
12/31/2022 | 49 | -182 | N/A | N/A | 4 |
6/30/2022 | 53 | -208 | -209 | -209 | N/A |
3/31/2022 | 38 | -236 | -211 | -210 | N/A |
12/31/2021 | 37 | -251 | -227 | -227 | N/A |
9/30/2021 | 34 | -267 | -229 | -228 | N/A |
6/30/2021 | 33 | -257 | -229 | -228 | N/A |
3/31/2021 | 22 | -251 | -250 | -224 | N/A |
12/31/2020 | 16 | -232 | -257 | -206 | N/A |
9/30/2020 | 12 | -222 | -239 | -189 | N/A |
6/30/2020 | 14 | -202 | -235 | -184 | N/A |
3/31/2020 | 17 | -192 | -200 | -174 | N/A |
12/31/2019 | 24 | -173 | -148 | -147 | N/A |
9/30/2019 | 29 | -140 | -135 | -134 | N/A |
6/30/2019 | 23 | -141 | -132 | -132 | N/A |
3/31/2019 | 30 | -122 | -123 | -123 | N/A |
12/31/2018 | 22 | -124 | -122 | -122 | N/A |
9/30/2018 | 12 | -137 | -130 | -129 | N/A |
6/30/2018 | 12 | -137 | -133 | -133 | N/A |
3/31/2018 | 10 | -136 | -119 | -118 | N/A |
12/31/2017 | 10 | -134 | -121 | -120 | N/A |
9/30/2017 | 10 | -133 | -112 | -111 | N/A |
6/30/2017 | 17 | -120 | -98 | -97 | N/A |
3/31/2017 | 8 | -120 | -105 | -104 | N/A |
12/31/2016 | 8 | -110 | -97 | -96 | N/A |
9/30/2016 | 8 | -97 | -97 | -97 | N/A |
6/30/2016 | 2 | -96 | -80 | -79 | N/A |
3/31/2016 | 2 | -94 | N/A | -76 | N/A |
12/31/2015 | 3 | -132 | N/A | -73 | N/A |
9/30/2015 | 12 | -125 | N/A | -72 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: EPE is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: EPE is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: EPE is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: EPE's revenue (37.6% per year) is forecast to grow faster than the German market (4.7% per year).
Ricavi ad alta crescita: EPE's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if EPE's Return on Equity is forecast to be high in 3 years time